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Abstract (word count=242/250) Background
The first episode of psychosis (FEP) is a critical period in the emergence of cardiometabolic risk.
Aims
We set out to explore the influence of individual and lifestyle factors on cardometabolic outcomes in early psychosis.
Method
A prospective cohort study of 293 UK adults presenting with FEP investigating the influence of socio-demographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use), and medication on cardiometabolic outcomes over the following 12 months.
Results
Rates of obesity and glucose dysregulation rose from 17.8% and 12% respectively at baseline to 23.7% and 23.7% at one year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 hours daily. We found no association between lifestyle at baseline or type of anti-psychotic medication prescribed with either baseline or one-year cardiometabolic outcomes. Median Hba1c rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their white counterparts. At 12 months, one third of those with BME heritage exceeded the threshold for pre-diabetes (HbA1c >39mmol/mol).
Conclusion
Unhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence however that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow
Introduction
People with psychotic illnesses die prematurely, mostly from natural causes, with markedly raised standardized mortality ratios for cardiovascular disease (3.6; 95%CI, 3.5-3.6), with young adults (4.5; 95%CI, 4.1-4.8), women (4.6; 95%CI, 4.5-4.7), and people of white ethnicity (4.9; 95% CI, 4.8-5.0) especially at risk (1) . Cardiometabolic dysregulation is evident even from the early stages of psychosis (2) and increases in the months after first presentation, with olanzapine having the most marked effect (3) . Clozapine also affects metabolism, with 55% exhibiting glucose dysregulation within three months of starting (4) . A recent meta-analysis reported that antipsychotics were associated with greater weight gain in Asian as opposed to Western studies, although very few studies looked directly at the effects of ethnicity (5) .
Evidence is needed to determine whether or not interventions to modify cardiometabolic risk can be targeted in first episode psychosis (FEP). Few studies have investigated whether health behaviours at presentation including diet, physical activity and substance use predict subsequent deterioration in cardiometabolic status. An exception is a recent prospective study of 101 people with FEP (6) which found that low aerobic fitness was a significant risk factor for metabolic syndrome (MetS).
Overall however, insufficient prospective observational studies have attempted to disentangle the impact of lifestyle on the emergence of cardiometabolic risk to reliably inform the development and targeting of effective preventative strategies.
The main aims of this study were therefore to a) to determine the prevalence of cardiometabolic risk factors in an ethnically diverse population at first presentation with psychosis; b) to describe the emergence of additional cardiometabolic risk over the year following first presentation with psychosis and c) to determine the relationship between lifestyle factors (diet, sedentary behaviour, smoking, substance use) and antipsychotic medication, in particular olanzapine and clozapine use, on cardiometabolic risk both at baseline and at 12 months follow up. We hypothesised that there would be an association between baseline lifestyle choices and (a) cardiometabolic risk at baseline and (b) prospectively in change in cardiometabolic risk over a one-year follow-up period. We also hypothesised that the emergence of glucose and lipid dysregulation would be greater in those prescribed the dibenzodiazepines, clozapine or olanzapine, compared to other antipsychotics.
Methods

Setting and Design
A prospective observational cohort of people was followed up for 12 months after their first presentation with psychosis. The study took place in inpatient and Early Intervention in Psychosis community mental health teams in three English Mental Health NHS services.
Eligibility criteria
Inclusion Criteria were as follows: a) aged between 16 and 65 years; b) within 6 months of first presentation with psychosis (ICD-10 codes F20-29 and F30-33)) c) proficient in English with no requirement for an interpreter. Patients were excluded if they were pregnant or had a major medical illness or neurological disease; diagnosed severe learning disability; an organic cause for their psychosis; or previous contact with health services for the presence of psychosis. All participants were included in the study only after giving written, confirmed consent. The study protocol was approved by the Joint South London and Maudsley and the Institute of Psychiatry NHS Research Ethics Committee (08/H0807/53).
Assessments
Patients were assessed at baseline and after 12 months. Sociodemographic data were recorded at baseline, namely age, sex, ethnicity (self-report) and years of education. The operational criteria checklist for psychotic and affective illness (OPCRIT) was used to assess type of mental health state over the lifetime (7) . All other measures were recorded at both 
Psychopathology
Mental health status was measured using the Positive and Negative Symptom Scale (PANSS) (8) , Global Assessment of Functioning (GAF) (9), Clinical Global Impression Scale (CGI) (10), Calgary Depression score (11) , and the Young Mania Rating Scale (YMRS) (12) .
Pharmacological History
Type(s) (British National Formulary definitions) of psychotropic medication and duration of antipsychotic (in days) were retrospectively extracted from electronic medical records.
Cardiometabolic measures
Metabolic measures comprised anthropometric measures of weight, height, body mass index (BMI), waist circumference and blood pressure (BP), as well as fasting blood samples for glucose, glycated haemoglobin (HbA1c), lipids and c-reactive protein (CRP Diabetes was diagnosed based on a HbA1c of ≥ 48mmol/mol (≥6.5%), or a fasting glucose ≥7.0 mmol/l or a prior diagnosis of diabetes. In keeping with recent guidance from the American Diabetes Association, an HbA1C of 39-47 mmol/mol (5.7-6.4%) was taken to indicate glucose dysregulation or a high risk of diabetes (13) . The IDF definitions of other cardiometabolic risk factors were used (14) . Insulin resistance was presented using the homeostasis model assessment (HOMA-IR), calculated from fasting glucose and insulin levels. Inflammation was estimated using high sensitivity C-reactive protein (CRP) as a marker.
Physical activity and Dietary intake
Physical activity was assessed by the International Physical Activity Questionnaire (15) , which has been validated in psychosis (16) . The self-report Dietary Instrument for Nutrition Education (DINE)(17) was used to assess dietary patterns over the previous week. Additional questions were included to account for sugar intake, the consumption of take-away food, carbonated drinks and adding either salt or sugar to food/drinks.
Substance use
Cigarette and tobacco consumption was measured using the Nicotine Dependence questionnaire (18) and alcohol use with the Alcohol Use Disorders Identification Test (19), where scores of 8 or more indicate hazardous and harmful alcohol use. A modified Cannabis Experience Questionnaire (CEQ-4) was used to enquire about lifetime and current use of substances (20, 21) and a urine drug screen requested.
Statistical Analysis
Descriptive data are presented in tabular form. Pairwise comparisons were done using t-tests for continuous and chi-squared tests for categorical outcomes.
Baseline associations between continuous scores for lifestyle and cardiometabolic factors
were investigated using unadjusted and adjusted linear regression models. were imputed using logistic regression, using augmented logistic regression where perfect prediction was detected (22) . Continuous variables were imputed using linear regression unless they appeared non-normal, in which case the predictive mean matching imputation method, drawing from 5 nearest neighbours, was used (23) .
Imputed datasets were then used to examine cross sectional associations between each lifestyle factor and cardiometabolic factor separately using linear regression, unadjusted and adjusted for pre-specified potential confounders of CVD risk, namely age, gender, ethnicity and pre-baseline number of days on antipsychotic medication. We further explored the crosssectional associations between use of dibenzodiazepine medications (yes/no) prior to baseline and cardiometabolic factors at baseline using the same model and potential confounders.
For each outcome (change in cardiometabolic factor) at 12 months we employed separate multiple imputation models (using the same method as above) using the outcome and the same variables at baseline. We then explored for each baseline lifestyle factor, separately, whether they were associated with change in cardiometabolic factors over the 12 months follow up period, unadjusted, and then adjusted for the above potential confounders, investigating associations between use of dibenzodiazepine medications between baseline and 12 months (yes/no) and cardiometabolic factors in the same way.
We separately assessed whether cardiometabolic factors at baseline differed between a) medicated participants with less or greater than 14 days of antipsychotic medication prior to baseline and b) medicated and un-medicated participants prior to baseline.
To account for multiple testing a stricter alpha of 0.01 was pre-specified as the significance level (24) . Tests with a p value between 0.01 and 0.05 were discussed as a trend and conclusions should be treated as explorative. Sensitivity analyses were carried out for all the analyses using complete cases from the full dataset, and also using a reduced dataset (with only participants with <5 variables of interest missing) prior to using multiple imputation to check the extent to which the original multiple imputation was plausible.
Results
We screened 11705 for eligibility; 971 were eligible of whom 321 ( Participants medicated prior to baseline had higher baseline average waist circumferences (+7.7 cm [95% CI: 2.0,13.4], p=0.009) compared to those unmedicated. Those who had received over two weeks antipsychotic medication prior to baseline had higher total cholesterol (+0.5 mmol/L [0.1, 0.8 95% CI]) (p=0.007) than those prescribed antipsychotics for less than 2 weeks (excluding those prescribed no antipsychotic) ( Supplementary Table 3 ).
At baseline, 57% consumed a carbonated drink daily, half (50%) drinking more than one 500ml bottle per day, while 21.4% of the total sample drank diet carbonated drinks daily.
Three-quarters (75.7%) consumed tea on a daily basis, most (90.8%) taking more than one cup, with 44% of the sample adding 2 teaspoons or more of sugar to each cup of tea. Salt was added to food during cooking by 66.5% of participants. 78.5% of the sample consumed take-away meals, three-quarters of whom (75.8%) did so more than once weekly.
Relationship between lifestyle/medication and cardiometabolic outcomes at baseline and 12 months follow up.
Baseline DINE fat scores, sedentary behaviour, AUDIT scores and pre-baseline olanzapine use
were not significantly associated with any of the baseline cardiometabolic outcomes either unadjusted or after adjusting for potential confounders (supplementary table 6 ). Nor did the linear regression models show any association between baseline lifestyle factors and change in any of the cardiometabolic outcomes over 12 months either unadjusted or after adjusting for potential confounders (table 4) . Nor was there evidence of a difference in change in cardiometabolic outcomes by 12 months between those participants prescribed olanzapine between baseline and 12 months and those not (unadjusted and adjusted) (table 4).
Sensitivity analyses using complete cases only gave similar results with no evidence of any associations. Sensitivity analyses using a reduced dataset prior to imputing also gave similar results.
Effects of gender and ethnicity
Rates of central obesity at baseline were higher in women (62.7%; n=37/59) than in men There was a trend towards lower total cholesterol at 12 months (p=0.04) in BME patients.
Though HbA1c levels at baseline were comparable, BME patients exhibited a significant increase in median HbA1c levels over 12 months (p<0.01), rising by 3.3 mmol/mol. In contrast, no change was evident in white patients (table 3) . Where only complete paired datasets were included in the analysis, median HbA1c rose in white patients by 1.1 mm/mol and by 3.3mmol/mol in participants from BME groups (supplementary table 5). HbA1c levels above 39mmol/mol were seen in 10% (4/40) of white participants and 34% (18/53) of those from BME groups at 12 months. There was no significant difference in ethnicity between those prescribed olanzapine and those not (chi 2 (3)-3.10, p=0.376).
Discussion
This comprehensive large-scale cohort study of patients with first episode psychosis prospectively considers the relationship between lifestyle factors, medication and cardiometabolic trajectories. Weight gain is the most obvious problem for many patients both cosmetically and for their health -here 17.8% were obese at onset, rising to 23.7% within one
year. A case has recently been made for obesity to be recognised as a chronic disease (25) to allow the preventative strategies needed at a population level; in psychosis, the rapidity of weight gain over the first year offers an unrivalled opportunity for prevention, with diet, exercise and medication being key targets. We noted high consumption of saturated fat, carbonated, high-sugar drinks, sweetened beverages and added salt. Calorie intake was further augmented by alcohol use ( Table 2) . Although neither fat intake nor alcohol use in the early weeks of psychosis predicted longer term outcomes in our population, the Keeping the Body in Mind program has successfully worked with dieticians and exercise physiologists to prevent weight gain using lifestyle interventions for all early in the disease process (26) .
We also found early emergence of glucose dysregulation; by one year twice as many people had HbA1c levels at or above the ADA glucose dysregulation range (Tables 1, 2 ). Diabetes is highly predictive of cardiometabolic disease and can have especially significant health impacts in people with psychosis, given the other practical challenges they may face.
There was a remarkably high baseline prevalence of tobacco smoking of 76.8%. Smoking confers an almost five-fold risk of mortality in people with schizophrenia (27) . Further, nicotine dependence after psychosis onset predicts both poor medication adherence and non-remission of psychosis (28) . It is therefore worrisome that we saw little reduction in smoking rates over time. Since this work was completed, many UK mental health hospitals have become smoke free environments (29) and although a recent trial has demonstrated that smoking cessation can be achieved in the community, work remains to be done to sustain quitting (30) . Rates of current cannabis use and lifetime use of other substances were high, in keeping with previous work (20) .
People with psychosis engage in low levels of physical activity (31) . Although physical activity at baseline did not predict cardiometabolic outcome in our study, by 12 months 40% of the sample were engaging in the 150 minutes of physical activity per week recommended by the World Health Organisation (WHO, 2014). Worryingly however, sedentary behavior changed little and CRP levels increased over time. Sedentary behavior is associated with inflammation in psychosis 32), while inflammation is in turn linked to cardiometabolic disease (33) . Both exercise and sedentary behavior are important targets for health promotion with studies underway to examine ways of changing patterns of behavior in clinical settings (34) .
Our regression analyses revealed no relationship between cardiometabolic outcomes and lifestyle, nor any effect of dibenzodiazepine medication, despite the high risk of weight gain demonstrated with olanzapine in other settings (3) . A high proportion were prescribed olanzapine as a first anti-psychotic, a practice now not recommended (35) . Of note, no participants were prescribed clozapine in the first year of their illness, in keeping with the reported mean lag time to starting clozapine of 47.7 months (SD = 49.7) (36) . The omission of clozapine is noteworthy as 23% of people presenting with their first episode of psychosis are treatment resistant from illness onset (37) .
Our sensitivity analyses illustrated the rapidity of cardiometabolic change in early psychosis; those exposed to antipsychotic medication for more than 14 days before baseline had higher cholesterol levels than those on antipsychotics for less than a fortnight, whilst those exposed to any antipsychotic medication had a larger waist circumference at baseline than did the antipsychotic naive.
Effects of ethnicity and gender
Males of white ethnicity appeared to have a particular vulnerability to emergence of central obesity, increasing their mean waist size by 4.9cm, while men of other ethnicities gained a more modest 1.6cm. These changes are clinically significant and the variation between ethnic groups was in keeping with findings in established psychosis (38) . Central obesity is a better predictor of CVD risk than is general obesity (39) , so this may relate to the lower hazard ratios seen for all-cause mortality in black African, black Caribbean and South Asian patients with SMI compared to their white British counterparts (40) .
Women were at risk of central obesity throughout, with 72.7% in that category by one year, again consistent with the local figure of 95% seen in women with established psychosis (38) .
Central adiposity in females is predictive of all-cause mortality in white, but not black women
Minority ethnic groups appeared vulnerable to emergent glucose dysregulation, with highly clinically relevant increases in median Hba1c of 3.3mmol/mol (Table 3, supplementary table   5 ), but no change seen in white patients. Within the non-diabetic range, this reflects a highly clinically significant shift in glycaemia in the BME group, with one third exceeding the ADA HbA1c threshold for pre-diabetes (13)(>39mmol/mol (5.7%)), although it is useful to note that some would not have been identified as at risk by current NICE Guidelines 
Strengths and limitations
This is to our knowledge the most comprehensive study to date examining the effects of lifestyle choice on emergent cardiometabolic risk. In conducting this study, we recruited an incident sample of people presenting to both inpatient and community services for the first time with psychosis and followed them up for one year, thereby capturing the period with the greatest change in physical health. The diverse nature of the population studied allows exploration of the effect of ethnicity on emergence of cardiometabolic risk. The use of multiple imputation on a reduced dataset allowed confidence in the results while retaining generalizability (43) .
The study must be interpreted taking into account a number of methodological aspects. Over half our patients required acute inpatient care at the time of recruitment and many had received treatment for some weeks before being well enough to consent to inclusion. To minimise this effect and minimise missing data, we therefore sought permission to use clinical data, where available and comparable, as well as adjusting for the number of days prescribed anti-psychotics before baseline in our analyses. Also, in follow-up studies there is a risk that attrition may not be random. Therefore, considerable efforts were made to minimise loss to follow-up with contact made with 81% (217/268) of the then eligible participants at 12months, although 73 participants declined 12-month follow-up. There was recompense for time but no financial incentivisation to remain in the study. Analysis showed no differences in baseline demographic or clinical attributes between completers and non-completers. The supplementary tables include a descriptive table of complete paired measures. We also note that while 89 people were prescribed olanzapine at baseline, some did not sustain that prescription throughout the study period, possibly because of emergent metabolic effects.
Finally, the number of statistical tests carried out was reasonably large and although we took a more conservative threshold of statistical significance, we cannot completely discount the possibility of Type I errors.
Conclusion
Our results identify that cardiometabolic risk factors are already pronounced in those presenting to FEP services and worsen over the first year under standard care. No baseline behaviour predicted risk of worsening cardiometabolic parameters, but a greater degree of emergent glucose dysregulation was observed in those from black and minority ethnicity groups.
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